Phase 2/3 Open-Label Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy
Status:
Not yet recruiting
Trial end date:
2028-12-28
Target enrollment:
Participant gender:
Summary
This is a phase 2/3 open-label study to evaluate the long-term safety, tolerability, and
efficacy of sibeprenlimab administered subcutaneously (SC) in subjects with IgAN.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Otsuka Pharmaceutical Development & Commercialization, Inc.